$Shuttle Pharmaceuticals Inc(SHPH)$ SHPH Explodes +31.29%: Volatility Spikes as Stock Reclaims $2 LevelLatest Close DataClosed at $2.14, up +31.29% from the previous close of $1.63. The stock remains significantly down, trading -91.5% below its 52-week high of $25.25.Core Market DriversExtreme volatility and a massive 144.78% intraday range were the primary drivers, with no specific news cited in the provided data. The surge in volume (127M shares, VR 99.49) and a 6580.97% turnover rate indicate intense speculative interest, potentially fueled by momentum trading or a short squeeze.Technical AnalysisThe explosive move is supported by surging volume and strong momentum indicators. The 6-day RSI jumped to 71.49, nearing overbought territory, while t
Bullish Points: 1. In September 2022, the company completed its initial public offering, generating net proceeds of $10,022,193. 2. In January 2023, the company entered into a Convertible Note agreement with a principal value of $4,300,000, providing $3,590,000 in net proceeds. 3. The company's existing cash resources are expected to provide sufficient funds for operations through the second half of 2024. 4. Cash and cash equivalents as of March 31, 2023: $7,169,268. 5. Marketable securities as of March 31, 2023: $2,991,771. 6. Research and development expenses include a $1,500,000 project with TCG GreenChem, with two milestone payments made so far. 7. The increase in R&D spending is primarily due to funding received from the Company's public offering in Q4 of fiscal 2022 and the conve
From an investment perspective, it's worth keeping an eye on companies that are involved in developing this treatment. If it becomes widely used, it could be a significant growth opportunity. $Shuttle Pharmaceuticals Inc(SHPH)$
$Shuttle Pharmaceuticals Inc(SHPH)$ It's always good to see new developments in cancer treatment, especially if they have the potential to improve outcomes for patients. I hope this method proves successful.
$Shuttle Pharmaceuticals Inc(SHPH)$ As a retail investor, I'm not sure how to evaluate the potential impact of this new cancer treatment method. Will it be effective? Will it be profitable for the companies involved?
don’t listen to the baggies on this board with gentle egos. Only buy when it’s showing demand/strength. It will be a much better outcome for you vs trying to catch a bottom off hopium. News doesn’t matter, it’s about supply and demand. That’s for all top gainers from today: $HeartCore Enterprises(HTCR)$$Shuttle Pharmaceuticals Inc(SHPH)$$CohBar, Inc.(CWBR)$
$CPHI $China Pharma(CPHI)$ $SHPH $Shuttle Pharmaceuticals Inc(SHPH)$ Thankful for these Hatteras Island night skies to see from the top deck after a nice day of gains. Shooting stars are always visible, normally within minutes. A kind reminder how small we are in this infinite universe. Cheers to ALL BULLS!
$SHPH $Shuttle Pharmaceuticals Inc(SHPH)$ Remember: in the last quarter hour, the price has moved between $2.95 and $3.10 and 1.5m shares have been traded, which is 5 times the volume of the last month excluding Friday and today. IMO it is a very bullish sign.
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.
09-24
Quarterly Report
Form 10-Q - Quarterly report [Sections 13 or 15(d)]